Compare · DXCM vs SGHT
DXCM vs SGHT
Side-by-side comparison of DexCom Inc. (DXCM) and Sight Sciences Inc. (SGHT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and SGHT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $23.67B, about 97.8x SGHT ($242.1M).
- Over the past year, DXCM is down 24.8% and SGHT is up 46.1% - SGHT leads by 70.9 points.
- Both names hit the wire about 8 times in the past 4 weeks.
- DXCM has more recent analyst coverage (25 ratings vs 19 for SGHT).
- Company
- DexCom Inc.
- Sight Sciences Inc.
- Price
- $61.33+3.02%
- $4.44+8.82%
- Market cap
- $23.67B
- $242.1M
- 1M return
- -1.65%
- +21.15%
- 1Y return
- -24.81%
- +46.05%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 8
- 8
- Recent ratings
- 25
- 19
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Sight Sciences Inc.
Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Latest DXCM
- SEC Form 10-Q filed by DexCom Inc.
- DexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Dexcom Reports First Quarter 2026 Financial Results
- Why Medtech Giants Are Quietly Paying Up for AI Diagnostics
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
- Amendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.
Latest SGHT
- Sight Sciences to Present at Two Upcoming Investor Conferences
- Sight Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Sight Sciences Announces the Release of its Sustainability Report
- SEC Form DEFA14A filed by Sight Sciences Inc.
- SEC Form DEF 14A filed by Sight Sciences Inc.
- Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026
- SEC Form 4 filed by Rodberg James
- SEC Form 4 filed by Hayden Jeremy B.
- SEC Form 4 filed by Bauerlein Alison
- SEC Form 4 filed by Badawi David